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Abstract 
Background: Conventional approaches to understand mechanisms underlying the development of pathological 
manifestations in ulcerative colitis (UC) mostly rely on identification of certain cell types and cytokines followed by 
verification of their roles in vitro and in vivo. In light of the highly dynamic processes in UC, requiring the cross talk of 
immune cells, epithelial-, endothelial-, muscle cells and fibrocytes, this approach might neglect temporal and spatial 
connectivity of individually differing inflammatory responses.
Methods: We undertook a more holistic approach whereby we designed a flow cytometric analysis- and ELISA panel 
and determined the immunological profiles of UC patients in comparison to Non UC donors. This panel consisted of 
B-cells, T-cells, macrophages, monocytes, NK- and NK T-cells and subtypes thereof, the cytokines TGFß1 and HGF, the 
chemokine TARC and periostin. Blood was collected from 41 UC patients and 30 non-UC donors. Isolated PBMC were 
subjected to flow cytometric analysis and sera were analyzed by ELISA. Data were analysed by cluster- and correla-
tion analysis. To corroborate that the identified cells reflected the inflammatory condition in the colon of UC patients, 
leucocytes were isolated from colons of UC patients and subjected to the same flow cytometric analysis.
Results: Immunological profiling followed by cluster- and correlation analysis led to the identification of two 
inflammatory conditions: An ‘acute’ condition characterized by adaptive immune cells as plasma cells,  TSLPR 
expressing CD11b+ macrophages, CD64 and CCR2 expressing CD14+ monocytes, HGF and TARC and a ‘remod-
eling’ condition signified by NK T-cells and TLSPR expressing CD14+ monocytes, TGFß1 and periostin. ROC analysis 
identified TARC and TGFß1 as biological markers with high potential to discriminate between these two condi-
tions (Δ = −6687.72 ng/ml; p = 1E−04; AUC = 0.87). In addition, CD1a+ CD11b+ macrophages (Δ = 17.73% 
CD1a+ CD11b+; p = 5E−04; AUC = 0.86) and CD1a+ CD14+ monocytes (Δ = 20.35; p = 0.02, AUC = 0.75) were 
identified as markers with high potential to discriminate between UC and Non UC donors. CD1a+ CD11b+ mac-
rophages and NK T-cells were found to be significantly increased in inflamed colons of UC patients as compared to 
non-UC control samples (p = 0.02).
Conclusions: Immunological profiling of UC patients might improve our understanding of the pathology underly-
ing individual manifestations and phases of the disease. This might lead to the development of novel diagnostics and 
therapeutic interventions adapted to individual needs and different phases of the disease. In addition, it might result 
in stratification of patients for clinical trials.
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Background
Ulcerative colitis (UC) belongs to the chronic inflam-
matory diseases of unknown etiology. Manifestations of 
the disease differ highly with regard to onset, severity, 
course and response to therapeutics and it is likely, that 
various forms of the disease are covered by the umbrella 
diagnosis of UC. It is presently thought that a combina-
tion of genetic, environmental and microbiotic factors is 
responsible for an uncontrolled immune response char-
acterized and driven by the typical Th2 cytokine Interleu-
kine (IL)-13 (for review see [1]). We have recently taken 
a slightly different view which is based on the assump-
tion that the inflammatory response partially resem-
bles an uncontrolled wound healing process caused 
by epithelial damage [2]. In this model an active role is 
assigned to epithelial cells as they release damage associ-
ated molecular pattern molecules (DAMP) such as TSLP 
(thymic stromal lymphopoietin) to direct immune cells 
towards a Th2 characterized immune response ultimately 
resulting in increased mucus production, epithelial cell 
hyperplasia and fibrosis. DAMPs comprise heterogene-
ous molecular entities ranging from toxic agents such 
as uric acid to proteases and allergens. The release of 
TSLP by epithelial cells can be induced by damage, sens-
ing microbial products or dsRNA via toll like receptors 
(TLR) [3–9]. This results in macrophages, dendritic cells 
(DC) and monocytes having the center stage because as 
the preferred targets of TSLP and as a highly volatile cel-
lular population they have the capacity to further fuel or 
dampen inflammation depending on the inflammatory 
milieu. The crucial role of macrophages in UC is sup-
ported by the efficacy of infliximab an anti-tumor necro-
sis factor (TNFα) monoclonal human antibody with IgG1 
effector function which is thought to be deleterious to 
macrophages expressing TNFα on their surfaces [10].
Wound healing processes are also governed by mac-
rophages. Here, neutrophils and inflammatory mac-
rophages (M1) infiltrate damaged tissue as a first step to 
protect the organism from pathogens. Once the wound 
is sealed macrophages engulf apoptotic neutrophils in 
a process called efferocytosis and in consequence alter 
their phenotype from inflammatory to healing (M2) [11, 
12]. Macrophages are main sources of hepatic growth 
factor (HGF), transforming growth factor (TGF) ß1 and 
thymus and activation regulated chemokine (TARC), all 
of which play a crucial role in wound healing processes 
and have been described as elevated in biopsies and/
or sera of UC patients [13, 14]. Hepatic growth factor 
induces re-epithelization and is expressed in fibroblast, 
monocytes, dendritic- and endothelial cells. HGF leads to 
proliferation, motility, IL-1ß, IL-4, GM CSF secretion and 
suppresses CD4+ and CD8+ cells [15]. TGFß1 induces 
fibrosis and scarring and additionally acts as an immune 
modulator. It is expressed in regulatory T-cells, M2 mac-
rophages, fibroblasts and platelets [16, 17]. TARC is 
expressed in epithelial cells, monocytes and macrophages 
and attracts CCR4 bearing Th2 cells, regulatory T-cells 
and macrophages into the damaged tissue [18, 19]. 
Finally, periostin is a protein associated with remodeling 
of the colon and lung architecture and expressed under 
the control of IL-13 which has been identified as a bio-
marker for patients responding to IL-13 therapy [20, 21]. 
Expressed by epithelial cells and fibroblasts and acting 
in an autocrine manner it induces collagen disposition, 
TGFß1 secretion, cell migration and epithelial to mesen-
chymal transition.
CD1a has been known for decades as a phenotypic 
marker of human epidermal Langerhans cells (LC). Like 
other members of the CD1 family CD1a presents lipids 
to evoke T cell activation resulting in the release of IL-22, 
IL-13 and interferon (IFN)γ [22, 23]. In the healthy skin 
auto reactivity is thought to be prevented by physical 
segregation of LC located in the epidermis and the cor-
responding lipid ligands concentrated in the stratum cor-
neum. Upon injury or inflammation segregation breaks 
down and LC activate autoreactive T-cells, notably Th22 
cells which are the major source of IL-22 production, 
which is thought to be instrumental in wound healing 
processes and antimicrobial defense [24–26]. The supply 
of fatty acid ligands can also be provided by phospholi-
pase A2 (PLA2) an important component of inflamma-
tion and bee- and wasp venom [27]. PLA2 releases fatty 
acids from phospholipids in the extracellular space where 
loading of CD1a takes place. To date, CD1a bearing mac-
rophages have not been detected in the colon.
To test our hypothesis of UC resembling an uncon-
trolled wound healing process we analyzed the immu-
nological profile of UC patients and compared these to 
those of Non UC donors by determining the frequency 
of immune cells in the blood and serum levels of TARC, 
HGF, TGFß1 and periostin. Cluster- and correlation anal-
ysis was performed to portray individual profiles and to 
understand the correlation of factors and immune cells 
in the inflammatory milieu of UC patients. In a second 
step, we analyzed immune cells isolated from colons of 
UC patients undergoing colectomy to verify that the cells 
identified as relevant in the blood reflected the inflamma-
tory condition in the colon.
Keywords: Ulcerative colitis, CD1a, HGF, TGFß1, TARC, Immune-profiling, Correlation analysis, Biomarker
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Methods
Ethical considerations
All donors gave informed written consent and the study 
was approved by the Institutional Review Board (IRB) 
of the Medical Faculty at the University of Munich 
(2015–22).
Colon samples and annotated data were obtained and 
experimental procedures were performed within the 
framework of the non profit foundation HTCR, including 
the informed patient’s consent [28].
Isolation of PBMC
Peripheral blood was collected from the arm vein of 
patients suffering from UC and Non UC donors. The 
Non UC donors had no apparent infection, inflamma-
tion and did not suffer from other chronic inflammatory 
diseases. As we could not exclude hidden infections 
they were considered as Non UC. 10  ml of blood in 
trisodium citrate solution were diluted with Hank’s bal-
anced salt solution (Thermofisher, Waltham, USA) in a 
1:2 ratio and 30 ml of the solution loaded onto Leuko-
sep tubes (Greiner Bio One, Frickenhausen, Germany). 
Cells were separated by centrifugation with 800g for 
30 min. The interphase containing PBMC was in Hanks 
balanced salt solution and centrifuged with 1400g 
for 5  min. The cell pellet was resuspended in sterile 
phosphate-buffered saline (PBS) at a concentration of 
4 × 106 cells in 100 µl.
Isolation of lamina propria leucocytes
For isolation of lamina propria mononuclear cells 
(LPMC) from human colons which were extracted 
from UC and colon cancer patients, a protocol modi-
fied of Hansson et al. [29] was used. A piece in the size 
of approximately 2 ×  2 cm of colonic wall were kept in 
1× RPMI (Thermofisher, Waltham, USA) containing 10% 
FCS on ice until preparation. The mucosa was dissected 
of underlying muscular layers and fat with scissors and 
cut into small pieces <5 mm.
The tissue was predigested for 4 × 15 min in 15 ml pre-
digestion solution containing 1× HBSS (Thermofisher, 
Waltham, USA), 5  mM EDTA, 5% FCS, 100  U/ml Pen-
cillin–Streptomycin (Sigma-Aldrich Co.,St. Louise USA) 
in an orbital shaker with slow rotation (40  g) at 37  °C. 
To remove epithelial cells, cell suspensions were fil-
tered through a nylon filter. Following removal of excess 
EDTA with RPMI the pieces were cut into finer pieces 
of <1 mm and digested for 60 min in digestion solution 
containing 1× RPMI, 10% FCS, 1  mg/ml collagenase A 
(Sigma-Aldrich Co., St. Louise USA), 10 KU/ml Dnase I 
(Sigma-Aldrich Co., St. Louise USA), 100  U/ml Pencil-
lin–Streptomycin (Sigma-Aldrich Co., St. Louise USA) in 
an orbital shaker with slow rotation (40 g) at 37 °C.
Isolated LPMC were collected by centrifugation with 
177 g for 10 min and resuspended for FACS analysis. Cell 
suspensions were filtrated one more time using a 35 µm 
cell strainer for further purification before labelling the 
cells for flow cytometry analysis.
Flow cytometric analysis
Cellular markers to phenotype UC patients and healthy 
controls are depicted in Table 1.
Labelling of human leukocytes was performed as 
described in Table  1. All anti human antibodies were 
purchased from Biolegend (San Diego, USA) and used 
according to manufacturer’s instructions. Samples were 
measured using a BD FACS Canto II™ and analysed with 
FlowJo 10.1-Software (FlowJo LLC, Oregon, USA).
ELISA analysis
Human serum TARC, HGF, TGFß1, periostin, levels 
were measured via Enzyme linked Immunosorbent Assay 
(ELISA) (Biotechne, Minneapolis, USA) according to the 
manufacturer’s instructions. Sample was measured in 
duplicates.
Statistical analysis
Statistical analysis was performed with R: A language 
and environment for statistical computing. R Founda-
tion for Statistical Computing, Vienna, Austria (3.2.2). 
URL https://www.R-project.org/. Variables were repre-
sented with mean, standard deviation, median, and IQR 
values. A two-sided t.test and a significance level = 0.05 
was used to compare two groups and for more than two 
groups ANOVA followed by TukeyHSD was conducted. 
Correlation analysis was performed using spearman rank 
correlation analysis. ROC curves were performed using 
R. Heatmap was performed using R (default).
Results
Immuno‑profiling of UC patients
In order to characterize the inflammatory condition, 
blood samples were collected from UC patients and 
Non-UC patients (Table  2). Peripheral blood mononu-
clear cells (PBMC) and sera were collected as described 
in “Methods” section and samples were subjected to flow 
cytometric analysis to determine the frequencies using 
surface markers of B-cells, T-cells, macrophages, mono-
cytes, dendritic cells, NK T- and NK cells and subtypes 
thereof (Table 1; gating strategy Additional file 1: Fig. S1).
As TARC, HGF, TGFß1 and periostin are considered 
important factors of wound healing processes serum lev-
els of these factors were also quantified.
As shown in Table  3 (complete data set in Addi-
tional file  1: Table S1) a significant decline in fre-
quencies was found plasma-cells, CD4+ and 
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activated CD4+  CD25+  cells, CD11b+  macrophages, 
CD11c+ dendritic cells in the patient group as compared 
to the Non UC group. In contrast, increased frequen-
cies of CD1a expressing CD11b+ macrophages, TSLPR-, 
CD1a-, and CD163 expressing CD14+  monocytes and 
NK T cells were observed. In addition, serum levels of 
HGF and TGFß1 were increased in the UC group.
As only a few therapeutically naïve patients partici-
pated in the study and as TNFα-blockers, glucocorti-
coid, mesalazine and immune-suppressors are supposed 
to suppress or modulate immunological responses 
albeit in different ways, these results did not necessar-
ily suggest that the observed differences were disease 
specific. Therefore, patients were further subdivided 
into groups treated with TNFα-blockers, glucocorti-
coids, mesalazine and immune-suppressing drugs and 
compared to the rest of the patient group. As shown 
in Table  3 treatment with the respective therapeutics 
affected frequencies of immune cells and serum con-
centrations of factors and resulted in opposing affects. 
In contrast to patients treated with glucocorticoids, 
mesalazine and immune-suppressors, patients treated 
with TNFα-blockers displayed lower frequencies of 
cells of the adaptive immune system to include plasma-
cells, TSLPR+  and mature CD11b+  macrophages and 
dendritic cells along with a decline in HGF and TARC, 
whereas frequencies of TSLPR+  CD14+  monocytes 
and serum levels of TGFß1 increased. Opposing effects 
were observed in the patient group treated with gluco-
corticoids. In this group, cells of the adaptive immune 
system were not suppressed. Frequencies of B-cells, 
switched memory B-cells, plasma cells and TSLPR 
expressing CD11b+  macrophages displayed increased 
frequencies along with and HGF and TARC serum lev-
els. Unswitched CD19+  CD27+  IgD+  B-cells, mature 
CD14+ monocytes, TGFß1- and periostin serum levels 
decreased in this group. Of note, patients treated with 
TNFα blockers did not regain the profile of Non UC 
patients.
Table 1 Cellular markers used in phenotyping of UC patients
MC monocyte, NK natural killer cell, TSLPR thymic stromal lymphopoietin protein, cDC conventional dendritic cell
Marker Definition References
CD19+ CD27+ IgD+ Unswitched memory B-cell [30]
CD19+ CD27+ IgD− Switched memory B-cell [30]
CD19+ CD38+ Plasma cell [30]
CD4+ CD25+ Activated CD4+ T-, regulatory T cells, Th2 cells [31, 32]
CD14+ MC [33]
CD14+ CD80+ CD86+ MC, mature [33–35]
CD14+ CCR2+ MC, tissue penetrating, inflammatory [36]
CD14+ TSLPR+ MC, expressing TSLPR
CD14+ CD64+ M1MC [37]
CD14+ CD163+ M2 MC, scavenging cells [35]
CD14+ CD1a MC CD1a expressing
CD11b+ cDC1 [33]
CD11b+ CD80/86+ cDC1, mature
CD11b+ CD1a+ cDC1 CD1a expressing
CD11b+ TSLPR+ cDC1 TSLPR expressing
CD3+ CD56+ NK T-cell [38]
CD3− CD56+ NK cell
CD3− CD56−, CRTH2+ CD127+ ILC2 [39–41]
Table 2 Baseline demographics, duration of  disease and   
therapy
UC N = 41 Non UC N = 30
Age (years)
 Mean (SD) 39.3 (18.8) 28.9 (11.0)
 Range 24–60 21–62
Gender, male, n (%) 21 (50) 7 (25)
Duration of UC (years)
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In the mesalazine treated group a decline of CD11c 
dendritic cells was observed. Like in the group treated 
with glucocorticoids, the group treated with immune-
suppressive drugs no negative affect was observed on 
B-cells and subtypes thereof. However, a decline in 
CD8+  T-cells, mature CD14+  monocytes was detected 
along with decreased TGFß1 serum levels. In contrast 
TARC serum levels were increased.
As CD11b+ CD1a+ and CD14+ CD1a+ seemed to be 
a cell population discriminating between Non UC and 
UC and frequencies of these cell types were unaffected by 
therapeutic interventions a ROC analysis was performed 
to evaluate the quality of this marker (Fig. 1). The anal-
ysis revealed a high specificity and sensitivity for CD1a 
expressing CD11b+ and CD14+ macrophages.
As in the UC group the disparity in age and dura-
tion of the disease was high, a correlation analysis was 
performed to exclude that age and/or duration of dis-
ease were responsible for observed differences. And 
indeed, antigen unexperienced CD8+ T-cells defined as 
CD44- cells correlated negatively with age whereas anti-
gen experienced T-cells (CD44+), CD11b and NK T-cells 
correlated positively with age (Additional file 1: Fig. S2). 
This observation is in agreement with previous data 
which also showed a decline of naïve T-cells and accumu-
lation of antigen-experienced T-cells [40]. Thus, the age 
effect might affect observations obtained from analyzing 
T-cells. With the exception of NK T-cells all of these cell 
types also correlated with duration of disease, indicating 
both parameters might affect these cell types.
In order to examine whether the selected immune-
cells and markers could serve to identify individual 
signatures resulting in defining subgroups of UC 
patients, collected data were further subjected to a 
cluster analysis and the result was displayed as a heat-
map. As shown in Fig. 2a UC patients clustered in three 
main groups. Group I was signified by high levels of 
CD11b+  CD1a+, TGFß1, unswitched B-cells, TSLPR 
expressing CD14+  monocytes. In contrast, HGF and 
TARC, plasma cells, CD19+  B-cells, TSLPR expressing 
Fig. 1 CD1a expressing macrophages and monocytes as disease specific markers. a Exemplary flow cytometric analysis of CD11b+ CD1a and 
CD14+ CD1a populations in PBMC from a Non UC donor and a UC patient. b ROC curve for CD11b CD1a+ (Non UC n = 31, UC n = 40) and 
CD14+ CD1a (Non UC n = 9, UC n = 27) in differentiating UC and Non UC patients
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CD11b+  macrophages were decreased. Group III dis-
played a counter image to this pattern and group II repre-
sented an intermediate pattern between group I and III. 
Patients treated with TNFα-blockers mainly clustered in 
group I and II, whereas patients treated with glucocorti-
coids were mainly detected in group III. Patients treated 
with mesalazine were evenly spread in all three groups 
and patients treated with immune-suppressing drugs 
were found in group II and III.
Patients with a simple clinical colitis activating index 
(SCCAI) ≥5 [41, 42] were considered as patients expe-
riencing a relapse. The fact that these patients mainly 
clustered in group III suggested less efficacy of gluco-
corticoids, mesalazine and immune-suppressing drugs 
as compared to TNFα-blockers and that the profile 
associated with patients in group III reflected a more 
active form of the disease than response to therapeutics. 
Boxplot analysis of the main discriminators corrobo-
rated the findings of the heatmap (Fig. 2b). TARC, HGF 
and TGFß1 expression as well as frequencies of plasma 
cells and TSLPR expressing CD11b+  macrophages and 
CD14+  monocytes were affected by treatment with 
TNF-α-blockers.
The expression and cluster analysis suggested that 
TARC and to a lesser degree TGFß1 could serve as a 
marker to discriminate between the active form and the 
form in remission. ROC analysis corroborated this obser-
vation and identified TARC and TGFß1 as markers with 
high potential to discriminate between the two inflam-
matory conditions (Fig. 2c).
As the profiling and cluster analysis suggested that 
mainly two immunological profiles prevailed in the UC 
patient group a correlation analysis was performed 
(Figs. 3, 4, 5, 6, 7). In addition to the examined immune-
cells, the cluster analysis included the clinical activity 
score (SCCAI-Score) [41] and HGF, TARC, TGFß1 and 
periostin.
Correlation analysis of the SCCAI‑Score with immune cells 
and serum factors
As shown in Fig.  3 the SCCAI Score positively cor-
related with switched memory B-cells, plasma  cells, 
TSLPR+  macrophages, M2 resident monocytes, HGF 
and TARC, whereas it negatively correlated with 
unswitched memory B-cells, TGFß1 and periostin, sug-
gesting that the adaptive immune cells along with TSLPR 
expressing macrophages play an important role during 
the active form of the disease and that HGF and TARC 
are hallmarks of this condition. In contrast, TGFß1 and 
periostin signified a second inflammatory condition 
which—due to the molecular function of the proteins—
most probably was characterized by remodeling or the 
colon architecture.
Correlation‑ and interrelation analysis of serum factors
To corroborate these observations correlation and inter-
relation analysis was performed with these serum mark-
ers. As shown in Fig. 4 HGF and TARC were positively 
correlated with each other and both factors were nega-
tively correlated with TGFß1 and periostin. Likewise, 
TGFß1 and periostin were positively correlated with 
each other further indicating that elevated or decreased 
concentrations of HGF/TARC and TGFß1/periostin 
reflected different inflammatory conditions.
Correlation‑ and interrelation analysis of TSLPR expressing 
macrophages and monocytes with immune cells and serum 
factors
TSLP is thought to be an important cytokine to pro-
mote a Th2 characterized inflammation in response 
to epithelial damage. Monocytes and dendritic cells 
exhibit the highest expression of the TSLP recep-
tor (TSLPR) and are therefore the preferred targets of 
TSLP. Measurement of TSLP in serum of UC patients 
in comparison to healthy subjects revealed a decline in 
TSLP concentrations in UC patients (data not shown), 
suggesting that either TSLP does not play a role in UC 
or monocytes and macrophages cells act as ‘TSLP sinks’. 
The strong therapeutic response to TNFa-blockers in 
CD11b+  TSLPR+  macrophages (Table  3), however, 
supported the latter idea.
TSLPR is expressed on CD11b+  macrophages and 
CD14+  monocytes, and as shown in Fig.  5 both cell 
types correlated negatively with each other. This pat-
tern was preserved with regard to unswitched B-cells, 
switched B-cells, plasma cells, M1 monocytes and the 
(See figure on next page.) 
Fig. 2 Immunological profiling leads to identification of distinct subgroups of UC patients. PBMC and serum were isolated from UC patients and 
subjected to flow cytometric analysis and ELISA, respectively. A Hierachically clustered heatmap based on frequencies of immune cells and serum 
levels of TGFß1, HGF and TARC. (linkage hierarchical cluster with euclidean distance). Simple clinical colitis activating index (SCCAI). B Boxplot 
analysis of concentrations of TARC, HGF and TGFß1 and plasma cells and TSLPR expressing CD11b+ macrophages and monocytes in dependence 
of diagnosis or treatment with TNFα-blockers and glucocorticoids. (UC patients n = 30, treated with TNFα blocker n = 16, Glucocorticoid n = 9, 
mesalazine n = 16, colectomized patients n = 5. C ROC curve for TARC (a) and TGFß1 (b) in differentiating group I+ II and III. TARC: 95% CI value 
0.74–0.97, 18 cases treated with TNFα-blocker, 23 cases no treatment with TNFα-blockers; TGFß1: 95% CI value: 0.59–0.9, 18 cases treated with TNFα-
blocker, 24 cases no treatment with TNFα-blockers
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expression of TARC, HGF, TGFß1 and periostin. When-
ever TSLPR+  expressing CD11b+  macrophages corre-
lated positively, TSLPR+  expressing CD14+  monocytes 
correlated negatively and vice versa.
Correlation‑ and interrelation analysis of NK T‑cells and ILC2 
with immune cells and serum factors
NK T-cells are considered a major source of IL-13 which 
is thought play a key role in inducing pathological mani-
festations in UC. In order to examine whether NK T-cells 
can be assigned to the identified inflammatory conditions 
these cells were also subjected to correlation analyses. 
As shown in Fig. 6 NK T-cells correlated positively with 
CD14+  TSLPR+  monocytes and TGFß1 which were 
both considered as markers of the ‘remodeling condition’. 
Conversely, NK T-cells correlated negatively with HGF 
and plasma cells which are considered as markers for the 
‘acute’ condition. The positive correlation of NK T-cells 
Fig. 3 Correlation analysis of the clinical activity score (SCCAI) with 
subtypes of immune cells and serum factors depicted as scatter plots. 
(method = Spearman, numbers display Spearman rank-order correla-
tion coefficients (rho-values) and p values
Fig. 4 Correlation- and interrelation analysis of TARC, HGF, TGFß1 and 
periostin depicted as scatter plots. (method = Spearman, numbers 
display Spearman rank-order correlation coefficients (rho-values) and 
p values
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Fig. 5 Correlation- and interrelation analysis of CD11b+ TSLPR+ macrophages and CD14+ TSLPR+ monocytes with subtypes of immune cells and 
serum factors depicted as scatter plots. (method = Spearman, numbers display Spearman rank-order correlation coefficients (rho-values) and p 
values
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with CD1a expressing CD11b+  macrophages might 
indicate that these cells also play a role in the remod-
eling of the colon architecture. ILC2 cells are thought as 
further source of IL-13 and IL-4 and as these cells also 
correlated positively with NK T-cells we hypothesized 
that ILC might act similarly as NK T-cells. And indeed, 
the correlations reflected the correlations of NK T-cells. 
Like NK T-cells ILC2 correlated positively with TGFß1, 
CD1a+  CD11b+  macropohages and additionally with 
periostin, and like NK T-cells ILC2 correlated negatively 
with HGF and plasma cells.
Correlation analysis of CD1a expressing macrophages serum 
factors
The correlations of CD11b+  CD1a macrophages with 
NK T-cells and ILC2 suggested an association of this cell 
type with the remodeling conditions. To corroborate this 
assumption, correlations of CD1a expressing CD11b+ mac-
rophages were further analyzed. As shown in Fig. 7 this cell 
type correlated negatively with HGF and TARC and posi-
tively with TGFß1, indicating that they might be involved in 
the remodeling condition. No correlations could be detected 
with CD14+ CD1a expressing monocytes.
Fig. 6 Correlation- and interrelation analysis of NK T-cells and ILC2 with subtypes of immune cells and serum factors depicted as scatter plots. 
(method = Spearman, numbers display Spearman rank-order correlation coefficients (rho-values) and p values
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The inflammatory condition in the colon of UC patients
In order to verify the relevance of the identified markers 
in the affected colon, colon samples from UC patients 
undergoing colectomy were analyzed with regard to the 
presence of leucocytes and compared to unaffected areas 
of colon samples from cancer patients (Fig.  8). Leuco-
cytes were isolated as described in “Methods” section 
and subjected to the same flow cytometric analysis as 
the leucocytes from blood samples (for complete data 
set see Additional file 1: Table S2, gating strategy Addi-
tional file 1: Fig. S3). Although frequencies of almost all 
cell types were increased in UC samples as compared to 
Non UC samples, a significant increase could only be 
determined for CD1a+  CD11b+  macrophages and NK 
T-cells both of which were significantly increased in the 
blood of UC patients. CD14+  CD1a+  monocytes just 
failed to reach significance (p =  0.08). CD11b express-
ing macrophages and monocytes and NK T-cells were 
the most abundant cell subpopulations in the inflamed 
colon.
Discussion
Most studies to characterize inflammatory processes 
in UC are based on defining roles of single cell types or 
interleukins, chemokines or growth factors in the human 
disease and to validate their roles in an animal model. 
This approach has tremendously improved the under-
standing of inflammatory mechanism underlying the 
disease and to develop therapeutics targeting previously 
Fig. 7 Correlation analysis CD11b+ CD1a+ macrophages with 
serum factors depicted as scatter plots. (method = Spearman, num-
bers display Spearman rank-order correlation coefficients (rho-values) 
and p values
Fig. 8 Comparison of frequency of leucocytes in colon samples of 
UC and Non UC patients. Leucocytes were isolated from colons of UC 
patients (n = 4) and Non UC patients (n = 5) undergoing colectomy. 
a Frequency of leucocyte; b Frequency of respective parent. Bars 
represent mean values and SD. A two-sided t-test and a significance 
level = 0.05 was used to compare groups
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identified as crucial components. However, this approach 
does not take into consideration that inflammatory pro-
cesses are rarely one dimensional and static but are 
better described as ‘mobilées’ in which there is cross-
talk between static cells such as epithelial-, endothelial-
muscle cells, fibrocytes and mobile inflammatory cells 
which can shift balances affecting the entire system in a 
time dependent manner. Therefore, we took a different 
approach.
First we analyzed frequencies of inflammatory cells 
in the blood and serum levels of certain factors of UC 
patients and compared them to Non UC patients. The 
selection of the subtypes of cells and the factors had a 
bias, as it was based on the hypothesis that part of the 
inflammation in UC resembled an uncontrolled wound 
healing process and therefore might be strongly influ-
enced by macrophages and monocytes. Based on this 
immune-cell- and ELISA panel several significant differ-
ences in frequencies or concentrations between Non-UC 
donors and UC patients could be identified. These cells 
included cell of the adaptive immunity as plasma cells, 
cells of the innate immunity acting as mediators for the 
adaptive immunity as dendritic cells, CD11b+  mac-
rophages and CD14+  monocytes and subtypes thereof 
as CD11b+ CD1a+ , CD14+ TSLPR+ , CD14+ CD1a+ , 
CD14+  CD163+, and cells of the innate immunity as 
NK T-, NK-cells and ILC2. In addition, HGF and TGFß1 
which also have been previously described as elevated 
displayed a significant increase in serum levels [13, 43].
With the exception of NK T-cells age did not affect 
these cell types. Age and duration of disease resulted in 
decreased frequencies of naïve CD8+ and increase of 
frequencies of central memory CD8+ T-cells. This obser-
vation is in agreement with previous results, which also 
described a loss of naïve T-cells and an accumulation 
of experienced T- cells with age [40]. Thus, age might 
diminish the effect of the disease on these cell types. The 
observed increase of NK T-cells, however, might not be 
ascribed solely to the disease phenotype but also to age.
Gender did not affect expression levels of the analyzed 
immune cells. Since few of the patients were therapeu-
tically naïve, one could not rule out that results were 
masked by a therapeutic effect on these cell types and 
factors. When UC patients were subdivided accord-
ing to the respective therapy, the analysis revealed that 
TNFα-blockers (infliximab or adalizumab) had a pro-
found effect on plasma cells, dendritic cells, TSLPR 
expressing CD11b+  macrophages and TSLPR express-
ing CD14+ monocytes. In this patient group, TARC and 
HGF serum levels were reduced, whereas TGFß1 levels 
were elevated. It is noteworthy that these patients—
although most of them were in remission—did not regain 
the profile of a non UC subject but seem to represent a 
specific inflammatory condition. Opposing effects were 
observed in the glucocorticoid treated group. Cells of 
the adaptive immunity were not affected and in contrast 
to the group treated with TNFα-blockers frequencies of 
TSLPR expressing CD11b+ macrophages were elevated. 
Likewise, TARC and HGF serum levels were elevated 
as opposed to the group treated with TNFα-blockers. 
Mesalazine and immuno-suppressive drugs induced 
minor effects in this analysis. The group treated with 
immuno-suppressors was similar to the glucocorticoid 
treated group. As some of these patients were unrespon-
sive to treatment, the observed effect might be due to the 
inflammatory condition and not the response to treat-
ment. The cellular subtypes unaffected by all treatments 
and significantly different in UC patients and Non UC 
donors were CD1a expressing CD11b macrophages and 
monocytes.
CD1a expressing CD11b+  macrophages and 
CD14+  monocytes emerged as cell types significantly 
associated with UC. Both cell types differentiated 
between UC and Non UC donors with high discriminat-
ing potential as shown by an AUC value of 0.86 and 0.75, 
respectively. To our knowledge, CD1a expressing mono-
cytes and macrophages have neither been associated with 
the gut nor with UC. The opposing effects of the treat-
ment with glucocorticoids and TNFα-blockers suggested 
that these treatments might sustain different inflamma-
tory conditions. This idea was supported by cluster- and 
correlation analysis. Unlike the previous analysis, cluster 
and correlation analysis can give information about indi-
vidual inflammatory signatures and the inter dependen-
cies of cells and factors. Both analyses suggested that two 
distinct inflammatory conditions prevail in UC patients: 
Treatment with TNFα-blockers induced a condition sig-
nified by CD14+  TSLPR+  monocytes which correlated 
positively with unswitched CD19+  B-cells and TGFß1 
and periostin, indicating that this condition represents 
an inflammatory condition characterized by remodeling 
of the colon architecture (Table  4). The fact that most 
patients in this group responded to treatment and were 
considered as in remission further supported the idea. 
Of note, this condition does not reflect the homeostatic 
condition found in Non UC subjects, but more of an 
uncontrolled remodeling condition. These data might 
be consistent with studies in patients with Crohn’s dis-
ease which describe increased stenosis in response to 
treatment with infliximab. NK T-cells are considered the 
main source of IL-13 in UC [44] and our data suggest, 
that IL-13 might be the cytokine playing a key role in the 
remodeling condition.
The second inflammatory condition could be more 
characteristic of an acute inflammation signified 
by TSLPR+  CD11b+  macrophages that correlated 
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positively with the SCCAI-Score, cells of the adap-
tive immunity, HGF and TARC. It is noteworthy that 
TSLPR+ CD11b+ and TSLPR+ CD14+ monocytes cor-
related negatively with each other, suggesting that treat-
ment with TNFα-blockers clearly suppresses the acute 
condition while promoting the remodeling condition 
(Table 4). Our model might explain why anrukinzumab, 
an anti-IL-13 monoclonal antibody was found to have no 
effect on clinical activity score mucosal healing, rectal 
bleeding or clinical remission rates [45]. It might be that 
IL-13 may exert its activity in the remodeling condition 
by inducing tissue fibrosis [46] and not during the acute 
phase of the disease.
Furthermore, in Crohn’s disease it has been described 
that patients progress from inflammation to stenosis 
over a long period of time [47], suggesting that these 
two inflammatory conditions might also be found in 
Crohn’s patients. Finally, as an increased obstruction was 
observed in patients treated with infliximab, this drug 
is contraindicated in patients with stenosis. Our model 
might give also an explanation to these findings.
In this snapshot study, the dynamics of the disease had 
not been taken into consideration. Thus, we cannot con-
clude from our data that the inflammatory conditions 
relate to different stages such as relapse or remission. 
Longitudinal studies and studies with therapeutic naïve 
patients in remission might provide more insight into the 
dynamics of the disease.
In the intestine the inflammatory milieu in homeosta-
sis and inflammation mainly depends on hematopoietic 
stem cell derived macrophages [48]. In the gut, mac-
rophages are replenished from the blood and infiltrate 
the mucosa in case of inflammation. According to a new 
concept macrophages are considered accessory cell types 
which support their client cells—notably mucosal epithe-
lial cells in the gut- with various functions. One major 
function is the clearance of apoptotic cells; however, in 
addition to this housekeeping function macrophages 
act as important sensors and can acquire functions on 
demand adapted to the inflammatory milieu ranging 
from pro-inflammatory to healing or regulatory [49]. This 
postmodern behavior challenges our view of the one-cell 
one-function approach in which the function of a cell can 
be identified by certain surface markers. Instead, we are 
confronted with a highly volatile cell population which 
shapes and is shaped by the inflammatory milieu. Thus, 
in the inflammatory condition of the gut epithelial cells 
might relay signals to macrophages and monocytes and 
depending of the presence or frequency of the TSLPR 
expressing macrophages or monocytes the outcome is 
tipped towards ‘acute’ or ‘remodeling’. Analysis of the 
second subtype of macrophages and monocytes, namely 
CD1a expressing CD11b+  macrophages, and CD14+ 
monocytes did not reveal a clear-cut functional segre-
gation although CD1a+  macrophages correlate mainly 
with cell types and factors of the remodeling condition. 
Further studies have to be performed to analyze whether 
both cell types evoke different or similar responses.
The identification of potentially significant markers 
in the blood of UC patients is based on the assumption 
that the influx of inflammatory cells into the colonic 
mucosa is not a unidirectional route. Due to disrupted 
endothelial layers or an active transport mechanism, cell 
trafficking occurs to and from both compartments. If 
this assumption is correct one has to find the cells iden-
tified as relevant in the blood also in the colon of UC 
patient. Analysis of leucocytes from colons of UC iden-
tified monocytes, and CD1a+  CD11b+  macrophages 
and NK T-cells as significantly different in comparison 
to normal tissue derived from cancer patients undergo-
ing colectomy. CD14+ CD1a+ monocytes just failed to 
reach significance. All three had been identified as sig-
nificantly elevated markers in the blood of UC patients. 
Whether this observation reflects increased emigration 
to the colon or increased adherence to the colon has to 
be elucidated.
Conclusions
Our results indicate that inflammation in UC is char-
acterized by two main conditions: An ‘acute’ con-
dition characterized by plasma cells, subtypes of 






CD19+ CD27+ IgD+ − +
CD19+ CD27+ IgD− + −
CD19+ CD38+ + −
CD4+ CD25 +
CD11b+ TSLPR+ + −
CD11b+ CD1a+ +
CD14+ TSLPR+ − +
CD14+ CCR2+ + −
CD14+ CD1a+ ? ?
CD14+ CD64+ +
CD3+ CD56+ +
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CD11b+  macrophages, TARC and HGF and a ‘remod-
eling’ condition signified by NK T-cells, subtypes of 
CD14+  monocytes, TGFß1 and periostin. This study 
shows that profiling followed by correlation- and inter-
relation analysis of immune cells and serum factors leads 
to a better understanding of the ongoing inflammation. 
This analysis provides an explanation for the failure of 
anrukinzumab to reduce clinical symptoms and the 
observed increased stenosis in patients treated with inf-
liximab. In addition, CD1a expressing monocytes and 
macrophages were identified as disease markers. We 
are confident that a holistic approach that will include 
a broader panel of immune cells and serum factors will 
result in defining subgroups of UC patients and will ulti-
mately lead to more personalized therapies.
Authors’ contributions
MF flow cytometric analysis of PBMC; PP flow cytometric analysis of human 
colon; UM statistical analysis; FB recruitment of patients, patient history; MS 
conception, analysis; RG conception, analysis of data, writing of the manu-
script. All authors read and approved the final manuscript.
Author details
1 Department of General Visceral, and Transplantation Surgery, Hospital 
of the LMU Munich, Nussbaumstr. 20, 80336 Munich, Germany. 2 Institute 
of Molecular Animal Breeding and Biotechnology, and Laboratory for Func-
tional Genome Analysis (LAFUGA), Gene Center, LMU Munich, 81377 Munich, 
Germany. 3 Institute for Medical Informatics, Biometry and Epidemiology, LMU 
Munich, Marchioninistr. 15, 81377 Munich, Germany. 4 Department of Medi-
cine II-Grosshadern, Ludwig-Maximilians-University (LMU), Marchioninistr. 15, 
81377 Munich, Germany. 
Acknowledgements
We thank Janina Caesar for excellent technical support and Simone Bre-
iteneicher for her strong support and assistance in recruiting patients. Our 
special thanks goes to the donors without their commitment this work could 
not have been possible. Finally, we thank Eric Whalley for critically reading the 
manuscript.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials




All donors gave written consent for publication of the data.
Additional file
Additional file 1: Figure. S1. Gating strategy for isolated human PBMC. 
Figure S2. Age and duration of disease affects subtypes of leucocytes in 
UC patients. Figure S3. Gating strategy for human leucocytes isolated 
from human colon. Table S1. Data set for the flow cytometric analysis 
of PBMC and serum levels of HGF, TARC, TGFß1 and periostin. Table S1A. 
UC patients/Non UC donors. Table S1B. UC Patients treated with TNFα 
blockers/all other patients. Table S1C. UC Patients treated with glucocor-
ticoids/all other patients. Table S1D. Patients treated with mesalazine/
all other patients. Table S1E. Patients treated with immuno-suppressive 
drugs/all other patients. Table S2. Analysis of human Colon.
Ethics approval and consent to participate
All donors gave informed written consent and the study was approved by 
the Institutional Review Board (IRB) of the Medical Faculty at the University 
of Munich (2015-22). Colon samples and annotated data were obtained and 
experimental procedures were performed within the framework of the non 
profit foundation HTCR, including the informed patient’s consent [28].
Funding
This work was funded by the Bundesministerium für Bildung und Forschung 
[Grant Number 03V0556].
Received: 10 June 2016   Accepted: 3 October 2016
References
 1. de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the 
art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27.
 2. Jovanovic K, Siebeck M, Gropp R. The route to pathologies in chronic 
inflammatory diseases characterized by T helper type 2 immune cells. 
Clin Exp Immunol. 2014;178:201–11.
 3. Asokananthan N, Graham PT, Stewart DJ, Bakker AJ, Eidne KA, Thomp-
son PJ, Stewart GA. House dust mite allergens induce proinflammatory 
cytokines from respiratory epithelial cells: the cysteine protease allergen, 
Der p 1, activates protease-activated receptor (PAR)-2 and inactivates 
PAR-1. J Immunol. 2002;169:4572–8.
 4. Vu AT, Baba T, Chen X, Le TA, Kinoshita H, Xie Y, Kamijo S, Hiramatsu K, 
Ikeda S, Ogawa H, et al. Staphylococcus aureus membrane and diacylated 
lipopeptide induce thymic stromal lymphopoietin in keratinocytes 
through the Toll-like receptor 2-Toll-like receptor 6 pathway. J Allergy Clin 
Immunol. 2010;126:985–93.
 5. Le TA, Takai T, Vu AT, Kinoshita H, Chen X, Ikeda S, Ogawa H, Okumura 
K. Flagellin induces the expression of thymic stromal lymphopoietin in 
human keratinocytes via toll-like receptor 5. Int Arch Allergy Immunol. 
2011;155:31–7.
 6. Li DQ, Zhang L, Pflugfelder SC, De Paiva CS, Zhang X, Zhao G, Zheng 
X, Su Z, Qu Y. Short ragweed pollen triggers allergic inflammation 
through Toll-like receptor 4-dependent thymic stromal lymphopoi-
etin/OX40 ligand/OX40 signaling pathways. J Allergy Clin Immunol. 
2011;128(1318–1325):e1312.
 7. Xie Y, Takai T, Chen X, Okumura K, Ogawa H. Long TSLP transcript expres-
sion and release of TSLP induced by TLR ligands and cytokines in human 
keratinocytes. J Dermatol Sci. 2012;66:233–7.
 8. Yamada T, Saito H, Kimura Y, Kubo S, Sakashita M, Susuki D, Ito Y, Ogi K, 
Imoto Y, Fujieda S. CpG-DNA suppresses poly(I:C)-induced TSLP produc-
tion in human laryngeal arytenoid fibroblasts. Cytokine. 2012;57:245–50.
 9. Takai T, Chen X, Xie Y, Vu AT, Le TA, Kinoshita H, Kawasaki J, Kamijo S, Hara 
M, Ushio H, et al. TSLP expression induced via Toll-like receptor pathways 
in human keratinocytes. Methods Enzymol. 2014;535:371–87.
 10. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-
TNF-alpha monoclonal antibody cA2 binds recombinant transmem-
brane TNF-alpha and activates immune effector functions. Cytokine. 
1995;7:251–9.
 11. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage 
activation. Nat Rev Immunol. 2008;8:958–69.
 12. Ferrante CJ, Leibovich SJ. Regulation of macrophage polarization and 
wound healing. Adv Wound Care (New Rochelle). 2012;1:10–6.
 13. Christophi GP, Rong R, Holtzapple PG, Massa PT, Landas SK. Immune 
markers and differential signaling networks in ulcerative colitis and 
Crohn’s disease. Inflamm Bowel Dis. 2012;18:2342–56.
 14. Srivastava M, Zurakowski D, Cheifetz P, Leichtner A, Bousvaros A. 
Elevated serum hepatocyte growth factor in children and young 
adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 
2001;33:548–53.
 15. Molnarfi N, Benkhoucha M, Funakoshi H, Nakamura T, Lalive PH. Hepato-
cyte growth factor: a regulator of inflammation and autoimmunity. 
Autoimmun Rev. 2014;14(4):293–303.
Page 16 of 16Föhlinger et al. J Transl Med  (2016) 14:310 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 16. Kajdaniuk D, Marek B, Borgiel-Marek H, Kos-Kudla B. Transforming growth 
factor beta1 (TGFbeta1) in physiology and pathology. Endokrynol Pol. 
2013;64:384–96.
 17. Werner S, Grose R. Regulation of wound healing by growth factors and 
cytokines. Physiol Rev. 2003;83:835–70.
 18. Saeki H, Tamaki K. Thymus and activation regulated chemokine (TARC)/
CCL17 and skin diseases. J Dermatol Sci. 2006;43:75–84.
 19. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: 
linking hemostasis, inflammation, and host defense. Microcirculation. 
2003;10:335–50.
 20. Parulekar AD, Atik MA, Hanania NA. Periostin, a novel biomarker of TH2-
driven asthma. Curr Opin Pulm Med. 2014;20:60–5.
 21. Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L, Muller SJ, Fahy JV. 
Roles of epithelial cell-derived periostin in TGF-beta activation, collagen 
production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA. 
2010;107:14170–5.
 22. de Jong A, Pena-Cruz V, Cheng TY, Clark RA, Van Rhijn I, Moody DB. CD1a-
autoreactive T cells are a normal component of the human alphabeta T 
cell repertoire. Nat Immunol. 2010;11:1102–9.
 23. de Jong A, Cheng TY, Huang S, Gras S, Birkinshaw RW, Kasmar AG, Van 
Rhijn I, Pena-Cruz V, Ruan DT, Altman JD, et al. CD1a-autoreactive T cells 
recognize natural skin oils that function as headless antigens. Nat Immu-
nol. 2014;15:177–85.
 24. Basu R, O’Quinn DB, Silberger DJ, Schoeb TR, Fouser L, Ouyang W, Hatton 
RD, Weaver CT. Th22 cells are an important source of IL-22 for host pro-
tection against enteropathogenic bacteria. Immunity. 2012;37:1061–75.
 25. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diepolder 
H, Marquardt A, Jagla W, Popp A, et al. IL-22 is increased in active Crohn’s 
disease and promotes proinflammatory gene expression and intes-
tinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol. 
2006;290:G827–38.
 26. Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 
system. Nat Rev Drug Discov. 2014;13:21–38.
 27. Bourgeois EA, Subramaniam S, Cheng TY, De Jong A, Layre E, Ly D, Salimi 
M, Legaspi A, Modlin RL, Salio M, et al. Bee venom processes human skin 
lipids for presentation by CD1a. J Exp Med. 2015;212:149–63.
 28. Thasler WE, Weiss TS, Schillhorn K, Stoll PT, Irrgang B, Jauch KW. charitable 
state-controlled foundation human tissue and cell research: ethic and 
legal aspects in the supply of surgically removed human tissue for 
research in the academic and commercial sector in Germany. Cell Tissue 
Bank. 2003;4:49–56.
 29. Uronen-Hansson H, Persson E, Nilsson P, Agace W. Isolation of cells from 
human intestinal tissue. Bio-protocol. 2014;4:e1092. http://wwwbio-
protocol.org/e1092.
 30. Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of 
human memory B cells. Semin Immunol. 2008;20:67–82.
 31. Lehmann J, Huehn J, de la Rosa M, Maszyna F, Kretschmer U, Krenn V, 
Brunner M, Scheffold A, Hamann A. Expression of the integrin alpha Ebeta 
7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. 
Proc Natl Acad Sci USA. 2002;99:13031–6.
 32. Zaunders JJ, Munier ML, Seddiki N, Pett S, Ip S, Bailey M, Xu Y, Brown K, 
Dyer WB, Kim M, et al. High levels of human antigen-specific CD4+ T cells 
in peripheral blood revealed by stimulated coexpression of CD25 and 
CD134 (OX40). J Immunol. 2009;183:2827–36.
 33. Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, 
Segura E, Tussiwand R, Yona S. Dendritic cells, monocytes and mac-
rophages: a unified nomenclature based on ontogeny. Nat Rev Immunol. 
2014;14:571–8.
 34. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage 
subsets. Nat Rev Immunol. 2011;11:723–37.
 35. Orme J, Mohan C. Macrophage subpopulations in systemic lupus erythe-
matosus. Discov Med. 2012;13:151–8.
 36. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev 
Immunol. 2005;5:953–64.
 37. Verreck FA, de Boer T, Langenberg DM, van der Zanden L, Ottenhoff TH. 
Phenotypic and functional profiling of human proinflammatory type-1 
and anti-inflammatory type-2 macrophages in response to microbial 
antigens and IFN-gamma- and CD40L-mediated costimulation. J Leukoc 
Biol. 2006;79:285–93.
 38. Thanapati S, Das R, Tripathy AS. Phenotypic and functional analyses of NK 
and NKT-like populations during the early stages of chikungunya infec-
tion. Front Microbiol. 2015;6:895.
 39. Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and 
NK cell recognition. Immunol Today. 1990;11:237–44.
 40. Vescovini R, Fagnoni FF, Telera AR, Bucci L, Pedrazzoni M, Magalini F, Stella 
A, Pasin F, Medici MC, Calderaro A, et al. Naive and memory CD8 T cell 
pool homeostasis in advanced aging: impact of age and of antigen-
specific responses to cytomegalovirus. Age (Dordr). 2014;36:625–40.
 41. Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR. Defining 
relapse of ulcerative colitis using a symptom-based activity index. Scand 
J Gastroenterol. 2003;38:164–71.
 42. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis 
activity index. Gut. 1998;43:29–32.
 43. Feng JS, Yang Z, Zhu YZ, Liu Z, Guo CC, Zheng XB. Serum IL-17 and IL-6 
increased accompany with TGF-beta and IL-13 respectively in ulcerative 
colitis patients. Int J Clin Exp Med. 2014;7:5498–504.
 44. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, 
Exley M, Kitani A, Blumberg RS, et al. Nonclassical CD1d-restricted NK T 
cells that produce IL-13 characterize an atypical Th2 response in ulcera-
tive colitis. J Clin Invest. 2004;113:1490–7.
 45. Reinisch W, Panes J, Khurana S, Toth G, Hua F, Comer GM, Hinz M, Page 
K, O’Toole M, Moorehead TM, et al. Anrukinzumab, an anti-interleukin 13 
monoclonal antibody, in active UC: efficacy and safety from a phase IIa 
randomised multicentre study. Gut. 2015;64:894–900.
 46. Fichtner-Feigl S, Fuss IJ, Young CA, Watanabe T, Geissler EK, Schlitt HJ, 
Kitani A, Strober W. Induction of IL-13 triggers TGF-beta1-dependent 
tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J 
Immunol. 2007;178:5859–70.
 47. Vermeire S, Van Assche G, Rutgeerts P. Review article: altering the natural 
history of Crohn’s disease—evidence for and against current therapies. 
Aliment Pharmacol Ther. 2007;25:3–12.
 48. Bain CC, Bravo-Blas A, Scott CL, Gomez Perdiguero E, Geissmann F, Henri 
S, Malissen B, Osborne LC, Artis D, Mowat AM. Constant replenishment 
from circulating monocytes maintains the macrophage pool in the 
intestine of adult mice. Nat Immunol. 2014;15:929–37.
 49. Okabe Y, Medzhitov R. Tissue biology perspective on macrophages. Nat 
Immunol. 2015;17:9–17.
